** Ahead of Q4 earnings for European pharma, Jefferies focuses on Sanofi's SASY.PA 2025 upside, while flagging earnings risks to Novo Nordisk NOVOb.CO, AstraZeneca AZN.L and GSK GSK.L
** "Generalist interest in EU Pharma is subdued," Jefferies says, citing macro rotation and U.S. political concerns
** The broker says Sanofi might miss Q4 sales and EPS consensus, but adds the focus will be on the size of the share buyback which it estimates at EUR 8 billion ($8.25 billion)
** It expects the French group's longer-term R&D spending increase, with confidence in its amlitelimab and duvakitug drugs, to be in focus
** It says Roche ROG.S may meet 2024 outlook and highlights the company's M&A areas of interest, pipeline prioritisation and longer-term growth in R&D spend
** Novartis NOVN.S might have lower-than-expected sales, but higher profits than expected in Q4, Jefferies says, noting the new product launches and Phase 3 of pelacarsen
** Following Eli Lilly's LLY.N pre-announced Q4, Jefferies expects Novo Nordisk to slightly miss sales and profit estimates
** Jefferies focuses on GSK's plans for long-acting HIV injectables, market trends for their drugs in the U.S. and China, and preparations for the re-launch of Blenrep
($1 = 0.9696 euros)
(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.